Dr. Reddy's Share Price: Profit mein aayi badi girawat! Margins ka pressure dikha, Share **86%** tuta

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Dr. Reddy's Share Price: Profit mein aayi badi girawat! Margins ka pressure dikha, Share **86%** tuta
Overview

Dr. Reddy's Laboratories ke investors ke liye Q4 FY26 ka result thoda disappointing raha. Company ka net profit saal dar saal **86%** gir kar sirf **₹221 Crore** reh gaya hai. Iski wajah hai margins ka kaafi tight ho jaana.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Achanak Profit Aisa Kyun Gira?

Asal mein, Dr. Reddy's Q4 FY26 mein profit mein badi girawat dekhne ko mili. Company ka net profit 86% kam ho gaya aur ₹221 Crore par aa gaya. Iska sabse bada reason tha gross profit margins ka ghata, jo pehle 55.6% tha woh ab sirf 44.8% ho gaya hai. Yeh sab margin compression ki wajah se hua, jisse profit par bohot pressure aaya.

Revenue Ka Kya Scene Hai?

Quarterly results toh kamzor rahe, q ki revenue 12% gir kar ₹7,516 Crore ho gaya. Global Generics segment mein revenue 13% aur Pharmaceutical Services and Active Ingredients (PSAI) segment mein 5.7% ki girawat aayi. Upar se expenses bhi badh gaye, Selling, General & Administrative (SG&A) expenses 15% badh kar ₹2,776 Crore ho gaye. Profit Before Tax (PBT) toh 90% gir gaya aur ₹199 Crore ho gaya.

Lekin, agar poore saal (full year) ki baat karein toh revenue mein thoda 3% ka badhotri dikhi hai, total ₹33,593 Crore.

Company Ne Dividend Bhi Diya Hai?

Haan, sab kuch bura nahi hai! Company ne ₹8 per share ka final dividend announce kiya hai. Record date July 10, 2026 hai.

Analysts Aur Competitors Kya Keh Rahe Hain?

Market mein Dr. Reddy's ko lekar thodi mili-juli rai hai. Analysts ka kehna hai ki stock ko 'Hold' karna chahiye aur unka average price target ₹1,327.14 hai. Competitors jaise Sun Pharma (jiska P/E 40.91x hai) aur Cipla (P/E 23.18x hai) bhi isi market mein hain. Sun Pharma ko zyada confidence mil raha hai.

Aage Kya Ho Sakta Hai?

US market mein inventory aur pricing pressure ki wajah se revenue kam hua hai. Lenalidomide sales mein bhi kami aayi hai. R&D expenses bhi 24% kam kar diye gaye, jisse future products par asar pad sakta hai. Company ko ab margins improve karne aur international pricing ko manage karne mein challenges face karne padenge. Generics launch hone se thoda fayda ho sakta hai, par abhi market cautious hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.